MX2021004531A - Nuevos usos. - Google Patents
Nuevos usos.Info
- Publication number
- MX2021004531A MX2021004531A MX2021004531A MX2021004531A MX2021004531A MX 2021004531 A MX2021004531 A MX 2021004531A MX 2021004531 A MX2021004531 A MX 2021004531A MX 2021004531 A MX2021004531 A MX 2021004531A MX 2021004531 A MX2021004531 A MX 2021004531A
- Authority
- MX
- Mexico
- Prior art keywords
- disclosure provides
- novel uses
- diseases
- treating
- dopamine
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004076 Dopamine D1 Receptors Human genes 0.000 abstract 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000006662 intracellular pathway Effects 0.000 abstract 1
- 238000009256 replacement therapy Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748517P | 2018-10-21 | 2018-10-21 | |
| PCT/US2019/057260 WO2020086481A1 (en) | 2018-10-21 | 2019-10-21 | Novel uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004531A true MX2021004531A (es) | 2021-09-10 |
Family
ID=70331921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004531A MX2021004531A (es) | 2018-10-21 | 2019-10-21 | Nuevos usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12194042B2 (enExample) |
| EP (1) | EP3866808A4 (enExample) |
| JP (1) | JP7480135B2 (enExample) |
| KR (1) | KR20210080418A (enExample) |
| CN (1) | CN113194955A (enExample) |
| AU (1) | AU2019364274C1 (enExample) |
| BR (1) | BR112021007571A2 (enExample) |
| CA (1) | CA3117148A1 (enExample) |
| IL (1) | IL282396A (enExample) |
| MX (1) | MX2021004531A (enExample) |
| WO (1) | WO2020086481A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220184240A1 (en) * | 2019-04-12 | 2022-06-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US12410175B2 (en) | 2019-09-03 | 2025-09-09 | Intra-Cellular Therapies, Inc. | Compounds |
| EP4284806A4 (en) * | 2021-01-27 | 2025-02-26 | Intra-Cellular Therapies, Inc. | Salt crystals |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1585771A (zh) * | 2001-11-09 | 2005-02-23 | 先灵公司 | 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂 |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| EP2939676A1 (en) * | 2007-12-06 | 2015-11-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| TW201206937A (en) * | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| CA2961212C (en) | 2014-09-17 | 2024-02-06 | Intra-Cellular Therapies, Inc. | Compounds and methods |
| EP4112053B1 (en) | 2016-10-11 | 2024-02-14 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) | Treatment of synucleinopathies |
-
2019
- 2019-10-21 WO PCT/US2019/057260 patent/WO2020086481A1/en not_active Ceased
- 2019-10-21 US US17/287,478 patent/US12194042B2/en active Active
- 2019-10-21 CN CN201980084405.9A patent/CN113194955A/zh active Pending
- 2019-10-21 MX MX2021004531A patent/MX2021004531A/es unknown
- 2019-10-21 EP EP19877180.0A patent/EP3866808A4/en active Pending
- 2019-10-21 KR KR1020217013853A patent/KR20210080418A/ko not_active Ceased
- 2019-10-21 JP JP2021521516A patent/JP7480135B2/ja active Active
- 2019-10-21 AU AU2019364274A patent/AU2019364274C1/en active Active
- 2019-10-21 BR BR112021007571-2A patent/BR112021007571A2/pt unknown
- 2019-10-21 CA CA3117148A patent/CA3117148A1/en active Pending
-
2021
- 2021-04-18 IL IL282396A patent/IL282396A/en unknown
-
2024
- 2024-12-03 US US18/967,095 patent/US20250090536A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113194955A (zh) | 2021-07-30 |
| JP2022505471A (ja) | 2022-01-14 |
| AU2019364274B2 (en) | 2024-10-17 |
| US20250090536A1 (en) | 2025-03-20 |
| BR112021007571A2 (pt) | 2021-07-27 |
| US20210379072A1 (en) | 2021-12-09 |
| WO2020086481A1 (en) | 2020-04-30 |
| US12194042B2 (en) | 2025-01-14 |
| KR20210080418A (ko) | 2021-06-30 |
| IL282396A (en) | 2021-06-30 |
| EP3866808A4 (en) | 2023-04-12 |
| JP7480135B2 (ja) | 2024-05-09 |
| AU2019364274C1 (en) | 2025-04-10 |
| EP3866808A1 (en) | 2021-08-25 |
| AU2019364274A1 (en) | 2021-06-03 |
| CA3117148A1 (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| MY199872A (en) | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | |
| MX2020011562A (es) | Agonistas del receptor de la hormona tiroidea y usos de los mismos. | |
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| MX2019013072A (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| PH12017500153A1 (en) | Compositions and methods of use for treating metabolic disorders | |
| MX2018005107A (es) | Composiciones y metodos para la terapia relacionada con la microbiota fecal. | |
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MY199382A (en) | Methods of treating circadian rhythm sleep disorders | |
| MY196448A (en) | Anti-Htra1 Antibodies and Methods of use Thereof | |
| MX2021014905A (es) | Células seguras e invisibles para el sistema inmunitario. | |
| EP4233911A3 (en) | Wound healing medicament | |
| TW201713333A (en) | Methods of treating a neurodegenerative disease | |
| MX2020000693A (es) | Compuestos de 1,8-naftiridinona, y usos de los mismos. | |
| MX2020007555A (es) | Anticuerpos potenciadores del factor h y usos de los mismos. | |
| MX2021006439A (es) | Reguladores del cftr y metodos para su uso. | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| AU2018262805A1 (en) | Peptides for treatment of diabetes | |
| AU2017408066A1 (en) | Novel treatment of mitochondrial diseases | |
| WO2015142865A3 (en) | Metakaryocidal treatments | |
| WO2019040104A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES |